You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

NK/T-cell

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Extranodal NK T Cell Lymphoma, NK-Cell Leukemia Trial in Xuzhou (Anti-CD56 CAR T)

Recruiting
  • Extranodal NK T Cell Lymphoma
  • NK-Cell Leukemia
  • Anti-CD56 CAR T
  • Xuzhou, Jiangsu, China
    The Affiliated Hospital of Xuzhou Medical University
Jul 10, 2023

NK-T-Cell Lymphoma, Extranodal Trial in Shanghai (4 cycles of ESA regimen with sandwiched radiotherapy, 2 cycles of ESA regimen

Not yet recruiting
  • NK-T-Cell Lymphoma, Extranodal
  • 4 cycles of ESA regimen with sandwiched radiotherapy
  • +2 more
  • Shanghai, Shanghai, China
    Ruijin Hospital
Sep 29, 2023

nk/T-cell Lymphoma, Newly Diagnosed, Advanced Lymphoma Trial in Beijing (XPO1 inhibitor)

Recruiting
  • nk/T-cell Lymphoma
  • +2 more
  • XPO1 inhibitor
  • Beijing, Haidian, China
    ChinaPLAGH
Apr 18, 2023

Extranodal NK/T-cell Lymphoma Trial (Sugemalimab, Placebo, Pegaspargase)

Not yet recruiting
  • Extranodal NK/T-cell Lymphoma
  • Sugemalimab
  • +4 more
  • (no location specified)
Jan 17, 2023

NK-T-Cell Lymphoma, Extranodal Trial (Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride

Not yet recruiting
  • NK-T-Cell Lymphoma, Extranodal
  • Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) regimen
  • (no location specified)
Mar 7, 2023

NK/T-cell Lymphoma Trial in Shanghai (Positron Emission Tomography/Magnetic Resonance (PET/MR))

Not yet recruiting
  • NK/T-cell Lymphoma
  • Positron Emission Tomography/Magnetic Resonance (PET/MR)
  • Shanghai, Shanghai, China
    Ruijin Hospital
Dec 14, 2022

T-Cell and NK-Cell Tumor Trial

Not yet recruiting
  • T-Cell and NK-Cell Neoplasm
    • (no location specified)
    Sep 28, 2023

    Extranodal NK/T Cell Lymphoma, Nasal Type Trial in Guangdong (IBI318(Recombinant human anti-PD1/PD-L1 bispecific antibody))

    Active, not recruiting
    • Extranodal NK/T Cell Lymphoma, Nasal Type
    • IBI318(Recombinant human anti-PD1/PD-L1 bispecific antibody)
    • Guangdong, China
      Sun Yat-sen University Cancer Center
    Oct 10, 2022

    NK/T Cell Lymphoma, Vascular Immunomother T Cell Lymphoma, Non-Hodgkin Lymphoma Trial in Guangzhou (GNC-038)

    Not yet recruiting
    • NK/T Cell Lymphoma
    • +2 more
    • Guangzhou, Guangdong, China
    • +1 more
    Jan 12, 2023

    Lymphoma Trial (Tislelizumab)

    Not yet recruiting
    • Lymphoma
    • (no location specified)
    Jul 28, 2022

    T-cell Non-Hodgkin Lymphoma, Lymphoma, Extranodal NK-T-Cell Trial in Busan, Daegu (Busulfan, Fludarabine)

    Recruiting
    • T-cell Non-Hodgkin Lymphoma
    • Lymphoma, Extranodal NK-T-Cell
    • Busan, Korea, Republic of
    • +1 more
    Aug 17, 2022

    Extranodal NK/T-cell Lymphoma Trial in Bangkok (B-MAD chemo)

    Active, not recruiting
    • Extranodal NK/T-cell Lymphoma
    • B-MAD chemotherapy
    • Bangkok, Thailand
      King Chulalongkorn Memorial Hospital
    May 7, 2022

    Lymphoma, Extranodal NK-T-Cell Trial in Shanghai (Pembrolizumab, Involved Field Radiation Therapy)

    Recruiting
    • Lymphoma, Extranodal NK-T-Cell
    • Shanghai, China
      Shanghai Rui-Jin Hospital
    Mar 29, 2022

    Peripheral T/NK Cell Lymphoma (R/R PTCL) Trial (YY-20394)

    Recruiting
    • Peripheral T/NK Cell Lymphoma (R/R PTCL)
    • Houston, Texas
      MD Anderson Cancer Center
    Oct 19, 2022

    Extranodal NK/T Cell Lymphoma Trial in Nanjing (Pegaspargase(P-GOD), Pegaspargase(PEMD))

    Not yet recruiting
    • Extranodal NK/T Cell Lymphoma
    • Nanjing, Jiangsu, China
      Hematological Department, People's Hospital of Jiangsu Province
    Jun 16, 2022

    T-Cell Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Angioimmunoblastic T-cell Lymphoma Trial in Saint Louis (WU-CART-007)

    Not yet recruiting
    • T-Cell Non-Hodgkin Lymphoma
    • +14 more
    • WU-CART-007
    • Saint Louis, Missouri
      Washington University School of Medicine
    Jan 17, 2023

    NK/T Cell Lymphoma Nos Trial (Brentuximab Vedotin in Combination with Tislelizumab)

    Not yet recruiting
    • NK/T Cell Lymphoma Nos
    • Brentuximab Vedotin in Combination with Tislelizumab
    • (no location specified)
    Apr 6, 2022

    Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type, Early Stage, Anlotinib Trial in Guangzhou (Sintilimab)

    Completed
    • Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type
    • +7 more
    • Guangzhou, Guangdong, China
      Sun Yat-Sen University Cancer Center
    Jun 6, 2022

    Lymphoma, T-Cell, Lymphoma, Extranodal NK-T-Cell Trial run by the NCI (Alemtuzumab (Campath), EPOCH)

    Completed
    Has Results
    • Lymphoma, T-Cell
    • Lymphoma, Extranodal NK-T-Cell
    • Bethesda, Maryland
      National Institutes of Health Clinical Center, 9000 Rockville Pi
    Feb 3, 2022

    Adult T-cell Leukemia/Lymphoma, Extranodal NK-/T-cell Lymphoma, Nasal Type, Enteropathy-Associated T-Cell Lymphoma Trial run by

    Not yet recruiting
    • Adult T-cell Leukemia/Lymphoma
    • +4 more
    • CC-486 (5-azacitidine)
    • +3 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Aug 17, 2022

    Extranodal NK/T-cell Lymphoma Trial in Korea, Republic of (VT-EBV-N, Placebo)

    Recruiting
    • Extranodal NK/T-cell Lymphoma
    • VT-EBV-N
    • Placebo
    • Busan, Korea, Republic of
    • +7 more
    Apr 28, 2022

    Extranodal Natural Killer/T-cell Lymphoma Trial in Nanjing (circulate free methylated EBV DNA)

    Not yet recruiting
    • Extranodal Natural Killer/T-cell Lymphoma
    • circulate free methylated EBV DNA
    • Nanjing, China
      The First Affiliated Hospital of Nanjing Medical University
    Apr 19, 2022

    Peripheral T Cell Lymphoma, PTCL, Extranodal NK/T-cell Lymphoma Trial in Worldwide (Tislelizumab)

    Completed
    Has Results
    • Peripheral T Cell Lymphoma
    • +18 more
    • Vancouver, British Columbia, Canada
    • +29 more
    Apr 29, 2022

    Mature T-Cell and NK-Cell Tumor Trial in Hwasun-gun (Copanlisib, Gemcitabine)

    Completed
    • Mature T-Cell and NK-Cell Neoplasm
    • Hwasun-gun, Jeollanam-do, Korea, Republic of
      Chonnam National University Hwasun Hospital
    Jun 9, 2022

    Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type, Early-stage, High-Risk Cancer Trial in Beijing (Anti-PD-1 mAb,

    Recruiting
    • Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type
    • +2 more
    • Anti-PD-1 monoclonal antibody
    • +4 more
    • Beijing, Beijing, China
      National Cancer Center/Cancer Hospital, Chinese Academy of Medic
    Feb 23, 2022